CardieX Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

CardieX şirketinin toplam hissedar öz sermayesi A$4.1M ve toplam borcu A$3.2M olup, bu da borç-öz sermaye oranını 79% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla A$12.6M ve A$8.6M dir.

Anahtar bilgiler

79.0%

Borç/özkaynak oranı

AU$3.23m

Borç

Faiz karşılama oranı	n/a
Nakit	AU$516.85k
Eşitlik	AU$4.09m
Toplam yükümlülükler	AU$8.56m
Toplam varlıklar	AU$12.65m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CDX 'nin kısa vadeli varlıkları ( A$10.4M ) kısa vadeli yükümlülüklerini ( A$8.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: CDX şirketinin kısa vadeli varlıkları ( A$10.4M ) uzun vadeli yükümlülüklerini ( A$485.2K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CDX 'nin net borç/öz sermaye oranı ( 66.3% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: CDX şirketinin borç/öz sermaye oranı son 5 yılda 59.4% seviyesinden 79% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: CDX şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: CDX un, serbest nakit akışı her yıl % 27.5 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

CardieX Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

CardieX Limited Auditor Raises 'Going Concern' Doubt

Recent updates

CardieX Limited, Annual General Meeting, Nov 29, 2024

Full year 2024 earnings released: AU$0.034 loss per share (vs AU$0.14 loss in FY 2023)

Full year 2024 earnings released: AU$0.038 loss per share (vs AU$0.14 loss in FY 2023)

New major risk - Market cap size

New major risk - Shareholder dilution

Less than half of directors are independent

CardieX Limited Appoints Charlie Taylor as an Independent Non-Executive Director, Effective 1 March 2024

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4 million.

CardieX Limited has filed a Follow-on Equity Offering in the amount of AUD 7.62 million.

CardieX Limited, Annual General Meeting, Nov 30, 2023

CardieX Limited Announces Resignation of Lesa Musatto as Independent Non-Executive Director

Full year 2023 earnings released: AU$0.15 loss per share (vs AU$0.12 loss in FY 2022)

New minor risk - Financial data availability

CardieX Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

CardieX Limited announced that it expects to receive AUD 2.3 million in funding

First half 2023 earnings released: AU$0.072 loss per share (vs AU$0.053 loss in 1H 2022)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.044413 million.

CardieX Limited Appoints Reid Yeoman as the Group's New Us Based Chief Financial Officer

CardieX Limited (ASX:CDX) acquired All the Assets of Blumio, Inc.

Less than half of directors are independent

CardieX Limited, Annual General Meeting, Nov 30, 2022

CardieX Limited Auditor Raises 'Going Concern' Doubt

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million.

Full year 2022 earnings released: AU$0.11 loss per share (vs AU$0.064 loss in FY 2021)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.330001 million.

CardieX Limited Announces FDA 510(K) Submission for Conneqt Pulse Dual Blood Pressure and Arterial Health Monitor

FDA Update for CONNEQT Companion App of Cardiex Limited

CardieX Limited Announces Appointment of Lesa Musatto as an Independent, Non-Executive Director

Less than half of directors are independent

CardieX Submits FDA Application for its CONNEQT App

Less than half of directors are independent

Global Health Technology Company CardieX and Mobvoi Launch a Revolutionary Heart Health Monitoring Smartwatch for Consumers

Full year 2021 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in FY 2020)

Full year 2021 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in FY 2020)

CardieX Launches CONNEQT™

CardieX Limited Announces New Devices on Track for Launch in 2021

CardieX Limited Announces Executive Appointments

CardieX Limited, Annual General Meeting, Dec 11, 2020

CardieX Limited Limited Announces Commercial Partnership Agreement with Mobvoi for New Health Smartwatch

Full year earnings released - AU$0.0046 loss per share

Full year earnings released - AU$0.0046 loss per share

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin